A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
To evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with metastatic her-2 positive colorectal cancer after standard treatment.
HER-2 Positive Colorectal Cancer
DRUG: Pyrotinib in combination with capecitabine
Maximally Tolerated Dose (MTD), Evaluation of tumor burden based on RECIST criteria., up to 36 months|Progression-free survival (PFS), Evaluation of tumor burden based on RECIST criteria., up to 36 months
Objective Response Rate (ORR), Evaluation of tumor burden based on RECIST criteria., up to 36 months|Duration Of Response (DOR), Evaluation of tumor burden based on RECIST criteria., up to 36 months|Disease Control Rate (DCR), Evaluation of tumor burden based on RECIST criteria., up to 36 months|Incidence of Treatment-Emergent Adverse Events [Safety], up to 36 months
To evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with metastatic her-2 positive colorectal cancer after standard treatment.